Pattern Recognition Receptors in Periodontal Disease: Molecular Mechanisms, Signaling Pathways, and Therapeutic Implications

Abstract

Periodontal disease remains a significant global health concern, characterized by complex host–pathogen interactions leading to tissue destruction. This review explored the role of pattern recognition receptors (PRRs) in the pathogenesis of periodontal disease, synthesizing current knowledge on their molecular mechanisms and potential as therapeutic targets. We examined the diverse family of PRRs, focusing on toll-like receptors (TLRs) and NOD-like receptors (NLRs), elucidating their activation by periodontal pathogens and subsequent downstream signaling cascades. This review highlights the intricate interplay between PRR-mediated pathways, including NF-κB and MAPK signaling, and their impact on inflammatory responses and bone metabolism in periodontal tissues. We discussed the emerging concept of PRR crosstalk and its implications for periodontal homeostasis and disease progression. Furthermore, this review addressed the potential of PRR-targeted therapies, exploring both challenges and opportunities in translating molecular insights into clinical applications. By providing an overview of PRRs in periodontal health and disease, this review aims to stimulate future research directions and inform the development of novel diagnostic and therapeutic strategies in periodontology.

1. Introduction

Periodontal disease, a chronic inflammatory condition affecting tooth-supporting structures, represents a global health challenge with far-reaching implications for oral and systemic health [1]. Recent advancements in molecular biology have elucidated the intricate pathways underlying its pathogenesis, offering novel perspectives for diagnosis and therapeutic interventions. A complex interplay between host immune responses and microbial challenges characterizes the molecular basis of periodontal disease. Central to this process is the activation of pattern recognition receptors (PRRs), particularly toll-like receptors (TLRs), by periodontal pathogens. Hajishengallis (2015) has elucidated how Porphyromonas gingivalis, a keystone pathogen in periodontitis, orchestrates a sophisticated manipulation of host responses, precipitating dysbiosis and perpetuating inflammation [2]. This microbial subversion of host immunity represents a critical juncture in the transition from periodontal health to disease. A pivotal molecular axis in periodontal pathogenesis is the RANKL/OPG system, which plays a crucial role in alveolar bone homeostasis. The systematic review by Hienz et al. has illuminated the significance of this pathway in periodontal bone loss, underscoring its potential as a therapeutic target [3]. The delicate balance between the receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) emerges as a key determinant in the osteoclastogenic processes that characterize periodontal tissue destruction.

The extracellular matrix degradation observed in periodontal disease is largely mediated by matrix metalloproteinases (MMPs). Sorsa et al. have provided evidence for the elevated levels of MMP-8 in oral fluids of periodontitis patients, highlighting its potential as a biomarker for disease activity [4]. This proteolytic enzyme serves not only as an indicator of ongoing tissue destruction but also as a potential therapeutic target for modulating disease progression. Epigenetic modifications have emerged as critical regulators of gene expression in periodontal disease. The seminal work of Larsson et al. has demonstrated differential DNA methylation patterns in gingival tissue samples from periodontitis patients compared with healthy controls, particularly in genes involved in immune responses and extracellular matrix organization [5]. These epigenetic alterations provide a novel layer of complexity to our understanding of periodontal disease pathogenesis and offer potential avenues for diagnostic and therapeutic innovations.

The periodontal microbiome’s influence on these molecular pathways cannot be overstated. Lamont et al. have elucidated how the oral microbiota interacts with host tissues, influencing health and disease states [6]. The transition from symbiosis to dysbiosis in the periodontal microbiome represents a critical event in disease initiation and progression, with far-reaching implications for host–microbe interactions and inflammatory cascades. Understanding these molecular pathways has opened new avenues for developing targeted therapies. For instance, the clinical trial by Hasturk et al. demonstrated that resolvin E1, a specialized pro-resolving mediator, significantly improved clinical parameters in periodontitis patients by modulating the inflammatory response [7]. This exemplifies the potential of molecular-targeted approaches in periodontal therapy. This systematic review aimed to synthesize current evidence on the molecular pathways implicated in periodontal disease progression, with a focus on the central role of pattern recognition receptors (PRRs), with particular emphasis on toll-like receptors (TLRs) and NOD-like receptors (NLRs), in initiating and perpetuating inflammation in periodontal disease. To analyze the downstream signaling cascades activated by PRRs, including the NF-κB and MAPK pathways, and their impact on inflammatory responses in periodontal tissues. The additional objectives were: 1. to explore the crosstalk between various PRRs and their interaction with other relevant molecular systems in the pathogenesis of periodontal disease, such as the RANKL/OPG axis; 2. to evaluate the role of PRRs in periodontal tissue homeostasis and the transition from health to disease, considering the influence of the periodontal microbiome; and 3. to investigate the influence of PRR genetic polymorphisms and possible epigenetic modifications associated with periodontal disease. By comprehensively analyzing these molecular pathways, we aimed to provide a nuanced understanding of periodontal disease pathogenesis at the molecular level. This synthesis of current knowledge will elucidate the etiology of periodontal disease and inform future diagnostic strategies and therapeutic interventions.

2. PRR-Mediated Signaling Cascades in Periodontal Disease

2.1. PRR Signaling Pathways in Periodontal Tissues

The activation of PRRs, particularly TLRs, in periodontal tissues initiates complex signaling cascades that play a crucial role in the pathogenesis of periodontitis. These pathways not only coordinate the immediate immune response but also influence tissue homeostasis and bone metabolism. TLR2 and TLR4 remain the most extensively studied PRRs in the context of periodontal disease [8], with their activation patterns significantly influencing disease progression and severity. Upon ligand binding, TLRs undergo conformational changes that facilitate the recruitment of adaptor proteins, primarily MyD88 (myeloid differentiation primary response 88), which is utilized by all TLRs except TLR3 [9,10]. This initiates a signaling cascade involving the sequential recruitment and activation of IRAK4 (interleukin-1 receptor-associated kinase 4) and IRAK1/2 [11]. The critical nature of IRAK4 in this process is evidenced by studies demonstrating that IRAK4-deficient mice show resistance to LPS-induced inflammatory responses [12]. In periodontal tissues specifically, IRAK4 activation proves essential for the production of pro-inflammatory cytokines through gingival epithelial cells responding to periodontal pathogens [13]. The signaling cascade progresses with the recruitment of TRAF6 (TNF receptor-associated factor 6), which functions as an E3 ubiquitin ligase, forming K63-linked polyubiquitin chains [14]. These ubiquitin modifications create a molecular scaffold that enables the recruitment and activation of TAK1 (transforming growth factor beta-activated kinase 1) and its associated proteins, TAB1 and TAB2/3 [15]. TAK1 activation represents a crucial junction in PRR signaling, leading to the activation of both NF-κB and MAPK pathways, which ultimately determine the inflammatory response’s magnitude and duration [16]. Recent research has revealed that these signaling cascades demonstrate remarkable tissue specificity in periodontal environments. For instance, gingival fibroblasts show distinct responses to PRR activation compared with periodontal ligament cells, particularly in their production of inflammatory mediators and tissue remodeling factors. Wang et al. demonstrated that TAK1 inhibition in human gingival fibroblasts significantly reduced pro-inflammatory cytokine production in response to P. gingivalis [17], highlighting the therapeutic potential of targeting specific nodes within these pathways. The integration of PRR signaling with bone metabolism pathways proves particularly relevant in periodontitis. These molecular cascades directly influence the RANKL/OPG axis, with PRR activation typically favoring RANKL expression and subsequent osteoclastogenesis. This connection provides a mechanistic link between bacterial recognition and the characteristic bone loss observed in periodontal disease. Furthermore, the sustained activation of these pathways in chronic periodontitis can lead to a self-perpetuating cycle of inflammation and tissue destruction [18].

2.2. NF-κB Activation in Periodontitis

NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation represents a pivotal molecular switch in the inflammatory response of periodontal disease [19,20]. This transcription factor family plays a central role in orchestrating immune responses by regulating the expression of numerous genes involved in inflammation, immune regulation, and tissue remodeling [21]. In unstimulated cells, NF-κB dimers are maintained in an inactive state through their association with inhibitory IκB proteins in the cytoplasm, preventing their nuclear translocation and subsequent transcriptional activity [22]. The activation of NF-κB in periodontal tissues follows a tightly regulated sequence of molecular events. TAK1 activation, resulting from upstream PRR signaling, leads to the phosphorylation and activation of the IKK (IκB kinase) complex. This complex, comprising IKKα, IKKβ, and IKKγ (NEMO), acts as a critical regulator of NF-κB signaling. Once activated, IKK phosphorylates IκB proteins, marking them for ubiquitination and subsequent proteasomal degradation [23]. The degradation of IκB liberates NF-κB dimers, allowing their translocation to the nucleus, where they can access their target genes and initiate transcription. In periodontal tissues, NF-κB activation induces a comprehensive inflammatory program. This includes the expression of:

• -. Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6);

• -. Chemokines (IL-8, MCP-1);

• -. Adhesion molecules (ICAM-1, VCAM-1);

• -. Matrix-degrading enzymes (MMPs);

• -. Osteoclastogenic factors (RANKL) [24,25].

The significance of NF-κB activation in periodontitis has been demonstrated through multiple lines of evidence. A seminal study by Arabaci et al. revealed increased nuclear localization of NF-κB p65 in gingival tissues from patients with chronic periodontitis compared with healthy controls [24]. This enhanced NF-κB activation correlated strongly with elevated levels of pro-inflammatory cytokines and more severe clinical parameters of periodontal disease. Furthermore, the persistent activation of NF-κB in periodontal tissues creates a self-perpetuating cycle of inflammation, as many of the products of NF-κB-dependent genes, such as IL-1β and TNF-α, can themselves activate NF-κB, establishing a positive feedback loop that contributes to disease chronicity [25]. The relationship between NF-κB activation and periodontal pathogens adds another layer of complexity to this pathway. P. gingivalis, through its various virulence factors, can modulate NF-κB activation in ways that promote its survival and persistence. For instance, its gingipains can selectively cleave specific cytokines while sparing others, allowing the bacterium to manipulate the local inflammatory environment [22,26]. Additionally, the ability of P. gingivalis to activate NF-κB through multiple PRRs (both TLR2 and TLR4) suggests a sophisticated level of host–pathogen interaction that contributes to disease progression. Recent research has also highlighted the role of NF-κB in linking inflammation to bone destruction in periodontitis. NF-κB activation in periodontal tissues not only drives inflammatory responses but also regulates the RANKL/OPG axis, a critical determinant of osteoclastogenesis. Through the induction of RANKL expression and the suppression of OPG, NF-κB signaling creates a molecular environment that favors bone resorption [27]. This mechanism provides a direct link between bacterial recognition, inflammatory responses, and the characteristic bone loss observed in periodontal disease. The therapeutic implications of NF-κB’s central role in periodontal inflammation are substantial. Various studies have explored the potential of targeting NF-κB signaling as a treatment strategy. Natural compounds with NF-κB inhibitory properties, such as resveratrol and curcumin, have shown promise in experimental periodontitis models [28]. However, given the ubiquitous nature of NF-κB signaling and its importance in normal physiological processes, the challenge lies in developing therapeutic approaches that can modulate its activity in a tissue-specific manner while maintaining its essential functions in host defense.

2.3. MAPK Signaling in Periodontal Inflammation

The mitogen-activated protein kinase (MAPK) cascades represent another crucial signaling axis in periodontal disease pathogenesis, operating parallel to and in concert with NF-κB signaling. These evolutionarily conserved pathways comprise three major branches: p38 MAPK, c-Jun N-terminal kinases (JNKs), and extracellular signal-regulated kinases (ERKs), each contributing distinctly to the inflammatory response and tissue destruction characteristic of periodontitis [29,30]. The activation of MAPK pathways in periodontal tissues follows a hierarchical phosphorylation cascade. Following PRR engagement and TAK1 activation, specific MAPK kinase kinases (MAP3Ks) initiate the cascade by phosphorylating MAPK kinases (MAP2Ks), which in turn activate the terminal MAPKs through dual phosphorylation of threonine and tyrosine residues. This precise molecular choreography ensures signal amplification and specificity in response to various periodontal pathogens and inflammatory mediators [31,32]. Among the MAPK pathways, p38 MAPK plays a dominant role in periodontal inflammation through its regulation of inflammatory cytokine production and tissue-destructive enzymes. A pivotal study by Kirkwood et al. demonstrated that p38 inhibition significantly reduced the production of inflammatory mediators by human periodontal ligament fibroblasts in response to periodontal pathogens [33]. This finding has particular relevance for therapeutic interventions, as p38 inhibitors have shown promise in experimental models of periodontitis. Furthermore, p38 MAPK regulates the expression of cyclooxygenase-2 (COX-2) and matrix metalloproteinases, directly linking this pathway to tissue destruction and bone loss [34]. The JNK pathway has emerged as a critical factor in alveolar bone loss during periodontitis. Through phosphorylation of c-Jun, a component of the AP-1 transcription factor complex, JNK signaling promotes RANKL expression in osteoblasts and periodontal ligament cells, stimulating osteoclastogenesis and subsequent bone resorption [35]. Recent studies have also revealed that P. gingivalis can manipulate JNK signaling to promote its survival within host cells, demonstrating the sophisticated interplay between periodontal pathogens and host signaling networks [36]. The ERK pathway, while often associated with growth and survival signals, exhibits context-dependent effects in periodontal disease. In response to periodontal pathogens, ERK signaling contributes to the production of pro-inflammatory cytokines and matrix metalloproteinases. However, it also plays essential roles in tissue repair and regeneration, highlighting the dual nature of this pathway in periodontal homeostasis [37]. The integration of these MAPK pathways creates a complex signaling network that determines the balance between tissue destruction and repair in periodontal disease. Recent research has revealed significant crosstalk between MAPK cascades and other signaling pathways. These interactions demonstrate synergistic activation patterns, where MAPK pathways can enhance NF-κB-dependent gene expression and amplify osteoclastogenic signals. The temporal regulation of these pathways, with different activation kinetics and sequential activation patterns, further influences cellular responses and determines disease progression [38]. The therapeutic potential of targeting MAPK pathways in periodontitis has generated considerable interest. Studies exploring specific MAPK inhibitors have shown promising results, particularly with p38 inhibitors in reducing inflammation and bone loss. However, the ubiquitous nature of MAPK signaling presents challenges for therapeutic targeting, necessitating careful consideration of tissue specificity and potential side effects [39]. Understanding the complex interplay between these pathways and their cell-type specific effects remains crucial for developing effective therapeutic strategies for periodontal disease.

2.4. Negative Regulation of TLR Signaling in Periodontitis

Given the potent inflammatory responses initiated by PRR signaling, the tight regulation of these pathways is crucial for preventing excessive tissue damage and maintaining periodontal homeostasis. Multiple endogenous mechanisms have evolved to control PRR-mediated inflammation, providing essential negative feedback loops that help resolve the inflammatory response and prevent chronic tissue destruction [39]. IRAK-M represents one of the primary negative regulators of TLR signaling in periodontal tissues. Unlike other IRAK family members, IRAK-M lacks kinase activity and functions as a negative regulator by preventing the dissociation of IRAK1 from the receptor complex [33]. In the context of periodontitis, IRAK-M expression becomes upregulated in chronic periodontal lesions, suggesting an adaptive response aimed at limiting excessive inflammation. Studies have demonstrated that IRAK-M-deficient mice exhibit enhanced inflammatory responses to periodontal pathogens, highlighting its crucial role in maintaining immune homeostasis [34]. The suppressor of cytokine signaling (SOCS) proteins, particularly SOCS1, constitute another essential regulatory mechanism in periodontal inflammation. SOCS1 demonstrates remarkable versatility in its regulatory functions, capable of inhibiting both NF-κB and STAT1 activation downstream of TLR signaling [35]. A groundbreaking study by Yoshimura et al. demonstrated that SOCS1 overexpression in gingival epithelial cells significantly attenuated their inflammatory response to P. gingivalis [36]. This finding suggests that SOCS1 functions as a critical molecular brake on inflammatory signaling in periodontal tissues. The ubiquitin-editing enzyme A20 emerges as another crucial negative regulator of PRR signaling in periodontal disease. A20 modifies ubiquitin chains on key signaling proteins, effectively terminating NF-κB activation and promoting signal resolution. Recent research has revealed that A20 expression becomes dysregulated in chronic periodontitis, potentially contributing to persistent inflammation. The restoration of normal A20 function represents a promising therapeutic avenue for managing periodontal inflammation [37]. Endotoxin tolerance represents a fascinating adaptation in periodontal tissues, whereby repeated exposure to bacterial products leads to a dampened inflammatory response. This phenomenon involves the coordinated action of multiple negative regulators and epigenetic modifications, resulting in a reprogrammed cellular response to bacterial challenges. In the context of periodontitis, endotoxin tolerance may serve as a protective mechanism against chronic inflammation, though its role in disease progression remains complex and context-dependent [38]. The temporal and spatial regulation of these inhibitory mechanisms proves critical for maintaining periodontal health. During the initial stages of infection, limited negative regulation allows for an effective antimicrobial response. However, as the inflammatory response progresses, these inhibitory pathways become increasingly important for preventing tissue damage. The balance between positive and negative regulation of PRR signaling ultimately determines the course of periodontal disease and the extent of tissue destruction [32]. Therapeutic approaches targeting these negative regulatory pathways have shown promise in experimental models of periodontitis. Enhancing the expression or activity of negative regulators like SOCS1 or A20 may provide novel strategies for controlling periodontal inflammation. However, the challenge lies in achieving tissue-specific modulation of these pathways while maintaining effective host defense against periodontal pathogens [37]. Genetic polymorphisms affecting the expression or function of these negative regulators may contribute to enhanced susceptibility to periodontitis, suggesting their potential utility as diagnostic markers or therapeutic targets. A schematic representation of PRR-mediated signaling cascades in periodontal disease is shown in Figure 1.

3. Pattern Recognition Receptors and Downstream Signaling Cascades in Periodontitis

3.1. TLR2 and TLR4: Central Players in Periodontal Inflammation

TLR2 and TLR4 remain at the forefront of PRR research in periodontitis, serving as primary sensors for periodontal pathogens. These receptors recognize a wide array of pathogen-associated molecular patterns (PAMPs) from periodontal bacteria, including lipopolysaccharide (LPS), lipoteichoic acid, and fimbriae. The periodontal tissues form a complex immunological environment, with TLRs being expressed by diverse cellular players including gingival epithelial cells, periodontal ligament fibroblasts, osteoblasts, and various immune cells, their expression often being amplified during inflammatory conditions [40]. A groundbreaking study by Hajishengallis et al. demonstrated that P. gingivalis, a keystone pathogen in periodontitis, selectively activates TLR2 while suppressing TLR4 responses [41]. This sophisticated manipulation of TLR signaling contributes to dysbiosis and chronic inflammation. The ability of P. gingivalis to modulate both TLR2 and TLR4 responses represents a critical virulence strategy, allowing the pathogen to evade host immunity while promoting an environment conducive to disease progression. Recent research has revealed novel mechanisms by which TLR2 activation in gingival epithelial cells leads to the production of matrix metalloproteinases (MMPs), particularly MMP-9, through the activation of MAPK and NF-κB pathways [39]. This finding provides a direct mechanistic link between bacterial recognition and tissue destruction in periodontitis. Furthermore, the cooperative interaction between TLR2 and TLR4 in periodontal tissues creates a sophisticated surveillance system that can distinguish between commensal and pathogenic bacteria, though this discrimination becomes compromised in disease states. The tissue-specific expression patterns of TLRs in the periodontium contribute significantly to local immune responses. Gingival epithelial cells, serving as the first line of defense, express both TLR2 and TLR4, allowing them to respond rapidly to bacterial challenges. However, excessive or prolonged activation of these receptors can lead to barrier dysfunction and increased tissue penetration by periodontal pathogens [36]. Of particular significance is the role of TLR2 and TLR4 in modulating bone homeostasis in periodontal tissues. These receptors influence the RANKL/OPG axis, with their activation typically promoting RANKL expression and subsequent osteoclastogenesis. This connection provides a direct link between bacterial recognition and alveolar bone loss, a hallmark of periodontal disease progression.

3.2. NOD-like Receptors: Emerging Players in Periodontal Immunity

While TLRs have been extensively studied, recent research has highlighted the crucial role of NOD-like receptors (NLRs) in periodontal host defense. These intracellular sensors recognize bacterial peptidoglycan fragments and have emerged as key regulators of inflammatory responses in periodontal tissues. NOD1 and NOD2, the best-characterized members of this family, have been shown to synergize with TLRs in amplifying inflammatory responses in periodontal disease [41].

A seminal study by Thay et al. demonstrated that NOD1 activation in oral epithelial cells by Aggregatibacter actinomycetemcomitans, a periodontal pathogen associated with aggressive periodontitis, leads to the production of pro-inflammatory cytokines and chemokines through the RIP2-dependent activation of NF-κB and MAPK pathways [42]. This NOD1-mediated response proved critical for neutrophil recruitment and bacterial clearance in vivo, highlighting its essential role in periodontal host defense. More recently, research has uncovered a specific role for NOD2 in regulating osteoclastogenesis in periodontitis. Studies by Lee et al. revealed that NOD2 activation in periodontal ligament fibroblasts leads to increased RANKL expression, promoting osteoclast differentiation and alveolar bone resorption [43]. This finding establishes a direct mechanistic link between bacterial recognition by NOD2 and the characteristic bone loss observed in periodontal disease. The interaction between NOD-like receptors and periodontal pathogens demonstrates remarkable complexity. P. gingivalis has evolved sophisticated mechanisms to modulate NOD signaling, potentially contributing to its persistence in periodontal tissues. This bacterial manipulation of NOD-dependent responses represents an important aspect of host–pathogen interactions in periodontal disease [42]. The synergistic interaction between NLRs and TLRs in periodontal tissues creates an integrated surveillance system for detecting and responding to periodontal pathogens. This cooperation leads to the enhanced production of inflammatory mediators and antimicrobial peptides, though excessive activation can contribute to tissue destruction. Understanding these complex interactions has revealed potential therapeutic targets for periodontal disease management. Of particular interest is the role of NOD2 polymorphisms in periodontal disease susceptibility. Genetic variations affecting NOD2 function have been associated with altered inflammatory responses and increased risk of severe periodontitis in certain populations. These findings suggest that NOD2 genetic screening might help identify individuals at higher risk for periodontal disease progression [41,43]. Recent research has also revealed the importance of NOD-like receptors in maintaining periodontal tissue homeostasis under normal conditions. Low-level activation of these receptors by commensal bacteria appears to contribute to barrier function and tissue repair, suggesting a dual role for NLRs in both homeostasis and inflammation [40].

3.3. Inflammasome Activation: A Double-Edged Sword in Periodontal Disease

The role of inflammasome activation, particularly the NLRP3 inflammasome, has gained significant attention in periodontal research. While inflammasome-mediated IL-1β production proves crucial for host defense, excessive activation can lead to destructive tissue inflammation. This complex protein assembly serves as a molecular platform for the processing and secretion of pro-inflammatory cytokines IL-1β and IL-18, playing a pivotal role in periodontal disease progression [44]. A comprehensive study by Yamaguchi et al. elucidated the mechanisms by which P. gingivalis activates the NLRP3 inflammasome in gingival fibroblasts [45]. Their research demonstrated that P. gingivalis* gingipains, cysteine proteases that are major virulence factors, induce NLRP3 activation through protease-activated receptor 2 (PAR2) signaling. This activation leads to pyroptosis, a form of inflammatory cell death, contributing to tissue breakdown in periodontitis. The two-signal activation process of the NLRP3 inflammasome, requiring both a priming signal often provided by TLR activation and a second signal triggered by various stimuli including bacterial toxins and cellular stress, highlights the complex regulation of this pathway in periodontal tissues. Intriguingly, Taxman et al. revealed a novel mechanism by which periodontal pathogens can suppress inflammasome activation [46]. They found that Filifactor alocis, an emerging periodontal pathogen, inhibits NLRP3 and AIM2 inflammasome activation in macrophages through a serine protease-dependent mechanism. This suppression of inflammasome activity may contribute to bacterial persistence and chronic inflammation in periodontitis, revealing the sophisticated strategies employed by periodontal pathogens to manipulate host immune responses [47]. The tissue-specific aspects of inflammasome activation in the periodontium have emerged as crucial factors in disease progression. Different cell types within periodontal tissues show distinct patterns of inflammasome assembly and activation. For instance, gingival epithelial cells and fibroblasts demonstrate different thresholds for NLRP3 activation, contributing to the spatial regulation of inflammatory responses [48]. Recent research has also highlighted the connection between inflammasome activation and alveolar bone loss in periodontitis. IL-1β, a key product of inflammasome activation, acts as a potent stimulator of osteoclastogenesis. Studies have demonstrated that excessive NLRP3 activation in periodontal tissues correlates with increased bone resorption and disease severity. This link provides a mechanistic explanation for the association between inflammasome activity and periodontal tissue destruction [49]. The regulatory mechanisms controlling inflammasome activation in periodontal tissues have attracted considerable attention. Various endogenous molecules, including oxidized mitochondrial DNA and extracellular ATP, can serve as danger signals triggering inflammasome assembly. Understanding these regulatory pathways has revealed potential therapeutic targets for managing periodontal inflammation [50]. Of particular clinical relevance, recent studies have explored the potential of targeting inflammasome activation as a therapeutic strategy in periodontitis. Small-molecule inhibitors of NLRP3, such as MCC950, have shown promise in various inflammatory disease models. While these approaches require further validation in periodontal disease, they represent an exciting avenue for therapeutic intervention [43,51].

3.4. PRRs and the Adaptive Immune Response in Periodontitis

The influence of PRR signaling on adaptive immune responses in periodontitis has emerged as a critical area of research, revealing complex interactions between innate and adaptive immunity. While PRRs are traditionally associated with innate immune responses, their activation significantly shapes the development and character of adaptive immune responses in periodontal tissues [31]. A groundbreaking study by Dutzan et al. demonstrated that TLR2 activation in gingival dendritic cells promotes the differentiation of T helper 17 (Th17) cells through the production of IL-23 and IL-1β [47]. These Th17 cells emerge as major producers of IL-17, a cytokine strongly associated with alveolar bone loss in periodontitis. The ability of PRRs to influence T cell differentiation represents a crucial link between bacterial recognition and the establishment of specific adaptive immune responses in periodontal disease. Furthermore, Moutsopoulos et al. uncovered a novel role for the C-type lectin receptor Dectin-1 in modulating T cell responses in periodontitis [41]. Their research revealed that Dectin-1 recognition of β-glucans from Candida albicans, an opportunistic fungal pathogen often present in periodontal pockets, leads to the expansion of T helper 1 (Th1) cells. This Th1 response, characterized by increased IFN-γ production, enhances bacterial clearance, suggesting a protective role for Dectin-1 in periodontitis. The interaction between PRRs and B cell responses adds another layer of complexity to periodontal immunity. TLR activation in antigen-presenting cells leads to the upregulation of co-stimulatory molecules and the production of B cell-activating factors. This process influences B cell differentiation and antibody production, potentially contributing to the development of autoimmune responses observed in some forms of periodontitis [22]. Recent research has highlighted the tissue-specific aspects of PRR-mediated adaptive immunity in the periodontium. The unique microenvironment of periodontal tissues, characterized by constant exposure to microbial products and mechanical stress, influences how PRR activation shapes local adaptive immune responses. For instance, gingival dendritic cells show distinct patterns of PRR expression and cytokine production compared with dendritic cells in other tissues, leading to specialized regulation of T cell responses [23,31]. The temporal dynamics of PRR-mediated adaptive immunity also prove crucial in periodontal disease progression. Initial PRR activation helps establish protective immune responses, but persistent activation can lead to destructive inflammation. The transition from acute to chronic disease involves complex changes in the balance between different T helper cell subsets and regulatory T cells, all influenced by ongoing PRR signaling [34]. Of particular significance is the role of PRRs in the maintenance of immune tolerance to commensal bacteria while maintaining the ability to mount effective responses against pathogens. This delicate balance relies on sophisticated crosstalk between PRRs and adaptive immune cells, with disruption of these regulatory networks potentially contributing to disease progression [25,29]. Understanding these complex interactions between PRRs and adaptive immunity has revealed new therapeutic opportunities. Approaches targeting specific aspects of this interaction, such as modulating dendritic cell PRR activation or influencing T helper cell differentiation, might offer novel strategies for managing periodontal disease. However, the challenge lies in maintaining protective immunity while preventing destructive inflammatory responses [46].

3.5. Crosstalk Between PRRs in Periodontal Disease

The complexity of the immune response in periodontitis is further increased by the crosstalk between different PRRs. The complexity of periodontal immune responses stems largely from the sophisticated interactions between different PRR families. This molecular crosstalk creates an intricate network of signaling pathways that ultimately determines the nature and magnitude of the inflammatory response. Recent research has revealed that these interactions play a crucial role in both homeostatic and pathological conditions in periodontal tissues [37]. The cooperation between TLRs and NOD-like receptors represents one of the best-characterized examples of PRR crosstalk in periodontal disease. When periodontal pathogens simultaneously activate both receptor families, the resulting inflammatory response often exceeds the sum of individual receptor activations. For instance, studies have demonstrated that concurrent activation of TLR2 and NOD2 by P. gingivalis components leads to synergistic production of pro-inflammatory cytokines in gingival epithelial cells [28]. This synergy involves shared downstream signaling components and coordinated activation of transcription factors, resulting in enhanced inflammatory responses. The interaction between cell surface and intracellular PRRs provides another layer of immune surveillance in periodontal tissues. While TLRs monitor the extracellular space and endosomal compartments, NOD-like receptors and other cytoplasmic sensors detect pathogens that breach cellular barriers. This multilayered detection system ensures comprehensive immune surveillance but can also contribute to excessive inflammation when dysregulated. Recent research has shown that the balance between these different PRR systems significantly influences periodontal tissue homeostasis [49]. Of particular importance is the crosstalk between PRRs and the NLRP3 inflammasome pathway. TLR activation provides the essential first signal for inflammasome assembly through the induction of NLRP3 and pro-IL-1β expression. This priming step works in concert with various second signals to regulate inflammasome activation. Recently, it has been demonstrated that this coordinated activation process becomes dysregulated in chronic periodontitis, contributing to persistent inflammation [50]. The spatial organization of different PRRs within periodontal tissues adds another dimension to their functional interactions. The distribution of various PRRs across different cell types and tissue compartments allows for coordinated immune responses but also creates opportunities for pathogen exploitation. For example, P. gingivalis has evolved mechanisms to manipulate this spatial organization by selectively activating or inhibiting specific PRRs in different cellular compartments [21]. Recent technological advances have revealed previously unknown aspects of PRR crosstalk. Single-cell analysis processing has demonstrated that individual cells can exhibit distinct patterns of PRR activation and interaction, contributing to the heterogeneity of immune responses in periodontal tissues. These findings suggest that the outcome of PRR crosstalk may vary depending on the specific cellular context and microenvironmental conditions [32]. Understanding the molecular mechanisms of PRR crosstalk has important therapeutic implications. Targeting multiple PRR pathways simultaneously might prove more effective than focusing on individual receptors. However, the challenge lies in maintaining beneficial aspects of PRR cooperation while preventing excessive inflammatory responses. Recent studies exploring combination therapies that modulate different aspects of PRR signaling have shown promising results in experimental models of periodontitis [13].

4. The Dual Role of PRRs in Periodontal Homeostasis and Disease

While PRRs are primarily known for their role in inflammatory responses, emerging evidence suggests they also play a part in maintaining periodontal tissue homeostasis under normal conditions. Recent studies have highlighted the potential of TLRs in promoting tissue repair and regeneration within the periodontium [19]. TLR activation has been shown to influence the function of periodontal ligament cells, indicating a role in tissue maintenance and potentially in regeneration. Interestingly, low-level activation of certain TLRs may contribute to the maintenance of epithelial barrier function in the gingiva [20]. This “physiological” level of PRR activation by commensal bacteria appears to be crucial for maintaining tissue homeostasis and preventing dysbiosis. This delicate balance underscores the complex role of PRRs in periodontal health.

4.1. PRRs at the Crossroads of Osteoimmunology and Periodontal Disease

The field of osteoimmunology has shed new light on the intricate relationship between the immune system and bone metabolism, a connection particularly relevant in the context of periodontitis-associated alveolar bone loss. PRR activation can significantly influence bone metabolism through modulation of the RANK–RANKL–OPG axis [21]. When TLRs in periodontal tissues are activated, it can lead to increased expression of RANKL, promoting osteoclastogenesis and bone resorption. The balance between RANKL and its decoy receptor OPG is crucial in regulating bone homeostasis. PRR-mediated inflammation can disrupt this balance, favoring bone resorption [22]. For example, P. gingivalis, a key periodontal pathogen, has been shown to induce RANKL expression through TLR2 activation, potentially contributing to alveolar bone loss in periodontitis. Furthermore, the NLRP3 inflammasome, activated downstream of various PRRs, has been implicated in periodontal bone loss [23]. IL-1β, a key product of inflammasome activation, is a potent stimulator of osteoclastogenesis. In periodontal tissues, the activation of the NLRP3 inflammasome has been associated with increased IL-1β production and subsequent tissue destruction [24]. This interplay among PRRs and the NLRP3 inflammasome represents a link between innate immune recognition and the destructive processes observed in periodontitis.

4.2. PRRs: Bridging Innate and Adaptive Immunity in Periodontal Disease

While PRRs are associated with innate immunity, their activation also plays a role in shaping the adaptive immune response in periodontal disease. The cytokines and chemokines produced as a result of PRR activation influence the differentiation and function of T cells and B cells [25]. TLR activation in antigen-presenting cells leads to the upregulation of co-stimulatory molecules and the production of cytokines that direct T cell differentiation. In the context of periodontitis, this can result in the polarization of T helper cells towards pro-inflammatory phenotypes, which have been associated with bone resorption and tissue destruction [26]. This connection between innate immune activation and adaptive immune responses underscores the central role of PRRs in orchestrating the overall immune response in periodontal disease. Understanding these complex interactions provides valuable insights into the pathogenesis of periodontitis and may offer new avenues for therapeutic interventions aimed at restoring periodontal health.

5. Discussion

The exploration of pattern recognition receptors (PRRs) in the pathogenesis of periodontal disease has unveiled a network of molecular interactions orchestrating the host immune response. The activation of PRRs, particularly toll-like receptors (TLRs) and NOD-like receptors (NLRs), emerges as a crucial event in the initiation and progression of periodontal inflammation. The complexity of these interactions is highlighted by the ability of periodontal pathogens to simultaneously activate multiple PRRs, as demonstrated for Porphyromonas gingivalis, which stimulates both TLR2 and TLR4 [17]. The downstream signaling cascade following PRR activation, primarily involving the NF-κB and MAPK pathways, plays a fundamental role in amplifying the inflammatory response. NF-κB activation induces the expression of numerous pro-inflammatory genes, including IL-1β, TNF-α, and IL-6, which significantly contribute to the tissue destruction and alveolar bone loss characteristic of periodontitis [27]. Modulation of these signaling pathways represents a potential therapeutic target, as suggested by studies on p38 MAPK inhibition, which has demonstrated reduced production of inflammatory cytokines and alveolar bone loss in animal models of periodontitis [30]. The activation of the NLRP3 inflammasome, a multiprotein complex part of the NLR family, emerges as another key player in the pathogenesis of periodontitis. Its activation leads to the secretion of IL-1β and IL-18, pro-inflammatory cytokines that promote tissue destruction [22]. The two-signal activation process of the NLRP3 inflammasome underscores the importance of crosstalk between different PRRs in modulating the periodontal immune response. The discovery of polymorphisms in PRR-encoding genes has provided new perspectives on individual susceptibility to periodontitis. Genetic variants of TLR2 and TLR4 have been associated with an increased risk of periodontitis in various populations [18,31]. These observations suggest that genetic variability in PRRs may influence the host’s ability to recognize and respond to periodontal pathogens, contributing to the variability in disease susceptibility and progression. The role of PRRs in periodontal tissue homeostasis represents an emerging and fascinating aspect of research. Low-level activation of TLRs by the commensal microbiota appears to contribute to the maintenance of the gingival epithelial barrier and the prevention of dysbiosis [20]. This physiological “tone” of PRR activation suggests a delicate balance between tolerance and immune reactivity in healthy periodontal tissues. In the context of osteoimmunology, the impact of PRRs on bone metabolism through modulation of the RANK–RANKL–OPG axis proves crucial for understanding alveolar bone loss in periodontitis. TLR activation can lead to increased RANKL expression, favoring osteoclastogenesis and bone resorption [21]. This mechanism provides a direct link between pathogen recognition and bone tissue destruction, characteristic of advanced periodontitis. The ability of PRRs to influence the adaptive immune response by modulating T cell differentiation and antibody production underscores their central role in orchestrating the overall immune response in periodontitis [25]. This interaction between innate and adaptive immunity mediated by PRRs may explain the chronic and progressive nature of periodontal disease. Despite significant advances in understanding the role of PRRs in periodontitis, several questions remain open. The complexity of interactions between different PRRs and their modulation by the oral microbiome requires further investigation. Moreover, translating this knowledge into effective therapeutic strategies remains a significant challenge.

6. Potential Therapeutic Applications

The elucidation of PRR-mediated pathways in periodontal disease pathogenesis opens up novel avenues for therapeutic interventions. One promising approach involves the modulation of TLR signaling. For instance, TLR4 antagonists have shown potential in reducing inflammation in various disease models [32]. In the context of periodontitis, targeting TLR4 could potentially mitigate the inflammatory response to lipopolysaccharide (LPS) from Gram-negative periodontal pathogens. Another potential therapeutic strategy involves the inhibition of downstream signaling molecules. The p38 MAPK inhibitor SB203580 has demonstrated efficacy in reducing periodontal inflammation and alveolar bone loss in animal models [30]. This suggests that targeting specific nodes in PRR signaling cascades could offer a more nuanced approach to managing periodontal inflammation, potentially avoiding the broad immunosuppression associated with some current therapies. The NLRP3 inflammasome presents another promising target. Small-molecule inhibitors of NLRP3, such as MCC950, have shown efficacy in various inflammatory disease models [33]. While not yet tested in periodontitis, these inhibitors could potentially reduce IL-1β production and subsequent tissue destruction in periodontal disease. Modulation of the RANK–RANKL–OPG axis represents a strategy to address periodontal bone loss directly. Denosumab, a monoclonal antibody against RANKL already used in osteoporosis treatment, has shown promise in preserving alveolar bone in periodontitis patients [34]. This approach exemplifies how insights from PRR-mediated osteoimmunology can translate into clinical applications. Probiotics and prebiotics offer an alternative approach to modulating PRR activation. By promoting a healthy oral microbiome, these interventions could potentially maintain the beneficial “tonic” PRR stimulation while preventing dysbiosis-induced excessive inflammation [35]. This strategy aligns with the emerging understanding of PRRs in maintaining periodontal tissue homeostasis.

7. Future Research Directions

While our understanding of PRRs in periodontal disease has advanced significantly, several key areas warrant further investigation. Firstly, the interplay between different PRR families in the context of polymicrobial infections characteristic of periodontitis remains to be fully elucidated. Future studies should aim to decipher how the activation of multiple PRRs by diverse periodontal pathogens shapes the overall immune response. The role of epigenetic modifications in regulating PRR expression and function in periodontal tissues represents another promising area of research. Epigenetic changes induced by chronic inflammation could potentially explain the persistence of dysregulated immune responses in periodontitis [36]. Understanding these mechanisms could lead to novel therapeutic approaches targeting epigenetic modifiers. The potential of PRRs as biomarkers for periodontal disease progression and treatment response merits further exploration. Longitudinal studies correlating PRR expression or activation levels with clinical outcomes could yield valuable prognostic tools. Advanced imaging techniques, such as intravital microscopy, could provide new insights into the spatiotemporal dynamics of PRR activation in periodontal tissues in vivo. This approach could help elucidate the complex interactions between host cells, the oral microbiome, and PRRs in the periodontal microenvironment. Finally, the translation of PRR-targeted therapies from preclinical models to human trials represents a critical next step. This will require careful consideration of the differences between animal models and human periodontal disease, as well as the potential systemic effects of modulating PRR signaling.

8. Conclusions

The study of pattern recognition receptors has transformed our understanding of periodontal disease pathogenesis. PRRs emerge as central orchestrators of the host response to periodontal pathogens, influencing inflammation, bone metabolism, and tissue repair processes. Their dual role in maintaining tissue homeostasis and driving pathological inflammation highlights the delicate balance of immune responses in periodontal health and disease. The identification of PRR polymorphisms associated with periodontitis susceptibility underscores the importance of host genetic factors in disease progression. Furthermore, therapeutic strategies targeting PRRs or their downstream signaling pathways show promise in preclinical models. However, translating these findings into clinical applications remains challenging, requiring careful consideration of the complex and multifactorial nature of periodontal disease.

Future research directions, including the exploration of PRR interactions in polymicrobial infections, epigenetic regulation of PRR function, and advanced in vivo imaging studies, will further refine our understanding of PRRs in periodontal health and disease. This expanding knowledge base continues to inform the development of innovative diagnostic tools and therapeutic interventions for periodontal disease management.

Author Contributions

Conceptualization, F.M.; formal analysis, F.M.; investigation, E.F. and F.M.; data curation, E.F.; writing—original draft preparation, F.M.; writing—review and editing, E.F.; visualization, E.F.; supervision, F.M.; project administration, F.M.; funding acquisition, E.F. All authors have read and agreed to the published version of the manuscript.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Figure

References

1. Kinane, D.F.; Stathopoulou, P.G.; Papapanou, P.N. Periodontal diseases. Nat. Rev. Dis. Primers; 2017; 3, 17038. [DOI: https://dx.doi.org/10.1038/nrdp.2017.38] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28805207]

2. Hajishengallis, G. Periodontitis: From microbial immune subversion to systemic inflammation. Nat. Rev. Immunol.; 2015; 15, pp. 30-44. [DOI: https://dx.doi.org/10.1038/nri3785]

3. Hienz, S.A.; Paliwal, S.; Ivanovski, S. Mechanisms of bone resorption in periodontitis. J. Immunol. Res.; 2015; 2015, 615486. [DOI: https://dx.doi.org/10.1155/2015/615486] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26065002]

4. Sorsa, T.; Gursoy, U.K.; Nwhator, S.; Hernandez, M.; Tervahartiala, T.; Leppilahti, J.; Gursoy, M.; Könönen, E.; Emingil, G.; Pussinen, P.J. et al. Analysis of matrix metalloproteinases, especially MMP-8, in gingival creviclular fluid, mouthrinse and saliva for monitoring periodontal diseases. Periodontol. 2000; 2016; 70, pp. 142-163. [DOI: https://dx.doi.org/10.1111/prd.12101]

5. Larsson, L.; Castilho, R.M.; Giannobile, W.V. Epigenetics and its role in periodontal diseases: A state-of-the-art review. J. Periodontol.; 2015; 86, pp. 556-568. [DOI: https://dx.doi.org/10.1902/jop.2014.140559] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25415244]

6. Lamont, R.J.; Koo, H.; Hajishengallis, G. The oral microbiota: Dynamic communities and host interactions. Nat. Rev. Microbiol.; 2018; 16, pp. 745-759. [DOI: https://dx.doi.org/10.1038/s41579-018-0089-x]

7. Hasturk, H.; Kantarci, A.; Goguet-Surmenian, E.; Blackwood, A.; Andry, C.; Serhan, C.N.; Van Dyke, T.E. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol.; 2007; 179, pp. 7021-7029. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17982093][DOI: https://dx.doi.org/10.4049/jimmunol.179.10.7021]

8. Takeuchi, O.; Akira, S. Pattern Recognition Receptors and Inflammation. Cell; 2010; 140, pp. 805-820. [DOI: https://dx.doi.org/10.1016/j.cell.2010.01.022]

9. Mahanonda, R.; Pichyangkul, S. Toll-like receptors and their role in periodontal health and disease. Periodontol. 2000; 2007; 43, pp. 41-55. [DOI: https://dx.doi.org/10.1111/j.1600-0757.2006.00179.x]

10. Hans, M.; Hans, V.M. Toll-like receptors and their dual role in periodontitis: A review. J. Oral Sci.; 2011; 53, pp. 263-271. [DOI: https://dx.doi.org/10.2334/josnusd.53.263]

11. Beklen, A.; Hukkanen, M.; Richardson, R.; Konttinen, Y.T. Immunohistochemical localization of Toll-like receptors 1–10 in periodontitis. Oral Microbiol. Immunol.; 2008; 23, pp. 425-431. [DOI: https://dx.doi.org/10.1111/j.1399-302X.2008.00448.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18793367]

12. Burns, E.; Bachrach, G.; Shapira, L.; Nussbaum, G. Cutting Edge: TLR2 Is Required for the Innate Response to Porphyromonas gingivalis: Activation Leads to Bacterial Persistence and TLR2 Deficiency Attenuates Induced Alveolar Bone Resorption. J. Immunol.; 2006; 177, pp. 8296-8300. [DOI: https://dx.doi.org/10.4049/jimmunol.177.12.8296]

13. Kawai, T.; Akira, S. TLR signaling. Semin. Immunol.; 2007; 19, pp. 24-32. [DOI: https://dx.doi.org/10.1016/j.smim.2006.12.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17275323]

14. Ambili, R.; Santhi, W.S.; Janam, P.; Nandakumar, K.; Pillai, M.R. Expression of activated transcription factor nuclear factor-κB in periodontally diseased tissues. J. Periodontol.; 2005; 76, pp. 1148-1153. [DOI: https://dx.doi.org/10.1902/jop.2005.76.7.1148] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16018758]

15. Graves, D. Cytokines That Promote Periodontal Tissue Destruction. J. Periodontol.; 2008; 79, pp. 1585-1591. [DOI: https://dx.doi.org/10.1902/jop.2008.080183]

16. Wang, C.; Deng, L.; Hong, M.; Akkaraju, G.R.; Inoue, J.I.; Chen, Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature; 2001; 412, pp. 346-351. [DOI: https://dx.doi.org/10.1038/35085597]

17. Kajiya, M.; Giro, G.; Taubman, M.A.; Han, X.; Mayer, M.P.; Kawai, T. Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease. J. Oral Microbiol.; 2010; 2, 5532. [DOI: https://dx.doi.org/10.3402/jom.v2i0.5532]

18. Sorsa, T.; Tjäderhane, L.; Konttinen, Y.T.; Lauhio, A.; Salo, T.; Lee, H.M.; Golub, L.M.; Brown, D.L.; Mäntylä, P. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann. Med.; 2006; 38, pp. 306-321. [DOI: https://dx.doi.org/10.1080/07853890600800103]

19. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol.; 2010; 11, pp. 373-384. [DOI: https://dx.doi.org/10.1038/ni.1863]

20. Takeda, K.; Akira, S. TLR signaling pathways. Semin. Immunol.; 2004; 16, pp. 3-9. [DOI: https://dx.doi.org/10.1016/j.smim.2003.10.003]

21. Kawagoe, T.; Sato, S.; Matsushita, K.; Kato, H.; Matsui, K.; Kumagai, Y.; Saitoh, T.; Kawai, T.; Takeuchi, O.; Akira, S. Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2. Nat. Immunol.; 2008; 9, pp. 684-691. [DOI: https://dx.doi.org/10.1038/ni.1606] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18438411]

22. Suzuki, N.; Suzuki, S.; Duncan, G.S.; Millar, D.G.; Wada, T.; Mirtsos, C.; Takada, H.; Wakeham, A.; Itie, A.; Li, S. et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature; 2002; 416, pp. 750-756. [DOI: https://dx.doi.org/10.1038/nature736]

23. Hasegawa, Y.; Mans, J.J.; Mao, S.; Lopez, M.C.; Baker, H.V.; Handfield, M.; Lamont, R.J. Gingival epithelial cell transcriptional responses to commensal and opportunistic oral microbial species. Infect. Immun.; 2007; 75, pp. 2540-2547. [DOI: https://dx.doi.org/10.1128/IAI.01957-06] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17307939]

24. Deng, L.; Wang, C.; Spencer, E.; Yang, L.; Braun, A.; You, J.; Slaughter, C.; Pickart, C.; Chen, Z.J. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell; 2000; 103, pp. 351-361. [DOI: https://dx.doi.org/10.1016/S0092-8674(00)00126-4] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11057907]

25. Arabaci, T.; Cicek, Y.; Canakci, C.F. Immunohistochemical and Stereologic Analysis of NF-κB Activation in Chronic Periodontitis. Eur. J. Dent.; 2010; 4, pp. 454-461.

26. Sato, S.; Sanjo, H.; Takeda, K.; Ninomiya-Tsuji, J.; Yamamoto, M.; Kawai, T.; Matsumoto, K.; Takeuchi, O.; Akira, S. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol.; 2005; 6, pp. 1087-1095. [DOI: https://dx.doi.org/10.1038/ni1255]

27. Hayden, M.S.; Ghosh, S. Shared principles in NF-κB signaling. Cell; 2008; 132, pp. 344-362. [DOI: https://dx.doi.org/10.1016/j.cell.2008.01.020] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18267068]

28. Graves, D.T.; Cochran, D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J. Periodontol.; 2003; 74, pp. 391-401. [DOI: https://dx.doi.org/10.1902/jop.2003.74.3.391]

29. Garlet, G.P. Destructive and protective roles of cytokines in periodontitis: A re-appraisal from host defense and tissue destruction viewpoints. J. Dent. Res.; 2010; 89, pp. 1349-1363. [DOI: https://dx.doi.org/10.1177/0022034510376402]

30. Kyriakis, J.M.; Avruch, J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol. Rev.; 2012; 92, pp. 689-737. [DOI: https://dx.doi.org/10.1152/physrev.00028.2011]

31. Kobayashi, K.; Hernandez, L.D.; Galán, J.E.; Janeway Jr, C.A.; Medzhitov, R.; Flavell, R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell; 2002; 110, pp. 191-202. [DOI: https://dx.doi.org/10.1016/S0092-8674(02)00827-9] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12150927]

32. Matsumoto, M.; Kogawa, M.; Wada, S.; Takayanagi, H.; Tsujimoto, M.; Katayama, S.; Hisatake, K.; Nogi, Y. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem.; 2004; 279, pp. 45969-45979. [DOI: https://dx.doi.org/10.1074/jbc.M408795200]

33. Liew, F.Y.; Xu, D.; Brint, E.K.; O’Neill, L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol.; 2005; 5, pp. 446-458. [DOI: https://dx.doi.org/10.1038/nri1630]

34. Kirkwood, K.L.; Cirelli, J.A.; Rogers, J.E.; Giannobile, W.V. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol. 2000; 2007; 43, pp. 294-315. [DOI: https://dx.doi.org/10.1111/j.1600-0757.2006.00166.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17214846]

35. Muthukuru, M.; Jotwani, R.; Cutler, C.W. Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect. Immun.; 2005; 73, pp. 687-694. [DOI: https://dx.doi.org/10.1128/IAI.73.2.687-694.2005]

36. Wang, L.; Wu, F.; Song, Y.; Duan, Y.; Jin, Z. Erythropoietin induces the osteogenesis of periodontal mesenchymal stem cells from healthy and periodontitis sources via activation of the p38 MAPK pathway. Int. J. Mol. Med.; 2018; 41, pp. 829-835. [DOI: https://dx.doi.org/10.3892/ijmm.2017.3294]

37. Groeger, S.; Jarzina, F.; Domann, E.; Meyle, J. Porphyromonas gingivalis activates NFκB and MAPK pathways in human oral epithelial cells. BMC Immunol.; 2017; 18, pp. 1-11. [DOI: https://dx.doi.org/10.1186/s12865-016-0185-5] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28056810]

38. Huang, W.; Zhan, Y.; Zheng, Y.; Han, Y.; Hu, W.; Hou, J. Up-regulated ferritin in periodontitis promotes inflammatory cytokine expression in human periodontal ligament cells through transferrin receptor via ERK/P38 MAPK pathways. Clin. Sci.; 2019; 133, pp. 135-148. [DOI: https://dx.doi.org/10.1042/CS20180679]

39. Xia, Z.; Li, Q.; Tang, Z. Network pharmacology, molecular docking, and experimental pharmacology explored Ermiao wan protected against periodontitis via the PI3K/AKT and NF-κB/MAPK signal pathways. J. Ethnopharmacol.; 2023; 303, 115900. [DOI: https://dx.doi.org/10.1016/j.jep.2022.115900]

40. Na, J.; Zheng, L.; Wang, L.; Shi, Q.; Yang, Z.; Liu, N.; Guo, Y.; Fan, Y. Phenytoin regulates migration and osteogenic differentiation by MAPK pathway in human periodontal ligament cells. Cell. Mol. Bioeng.; 2021; 15, pp. 151-160. [DOI: https://dx.doi.org/10.1007/s12195-021-00700-0]

41. Gu, Y.; Han, X. Toll-Like Receptor Signaling and Immune Regulatory Lymphocytes in Periodontal Disease. Int. J. Mol. Sci.; 2020; 21, 3329.PMC7247565[DOI: https://dx.doi.org/10.3390/ijms21093329] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32397173]

42. Hajishengallis, G.; Lambris, J.D. Microbial manipulation of receptor crosstalk in innate immunity. Nat. Rev. Immunol.; 2011; 11, pp. 187-200. [DOI: https://dx.doi.org/10.1038/nri2918] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21350579]

43. Thay, B.; Damm, A.; Kufer, T.A.; Wai, S.N.; Oscarsson, J. Aggregatibacter actinomycetemcomitans outer membrane vesicles are internalized in human host cells and trigger NOD1- and NOD2-dependent NF-κB activation. Infect. Immun.; 2014; 82, pp. 4034-4046.PMC4187862[DOI: https://dx.doi.org/10.1128/IAI.01980-14] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25024364]

44. Lee, S.I.; Kim, G.T.; Kim, H.J.; Park, S.H.; Kim, E.C. NOD2 Mediates Odontoblast Differentiation and RANKL Expression. J. Dent. Res.; 2014; 93, pp. 678-684. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24820666]PMC4293730[DOI: https://dx.doi.org/10.1177/0022034514535214]

45. Zhao, Y.; Quan, Y.; Lei, T.; Fan, L.; Ge, X.; Hu, S. The Role of Inflammasome NLPR3 in the Development and Therapy of Periodontitis. Int. J. Med. Sci.; 2022; 19, pp. 1603-1614. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36185327]PMC9515687[DOI: https://dx.doi.org/10.7150/ijms.74575]

46. Chen, Y.; Ye, X.; Escames, G.; Lei, W.; Zhang, X.; Li, M.; Jing, T.; Yao, Y.; Qiu, Z.; Wang, Z. et al. The NLRP3 inflammasome: Contributions to inflammation-related diseases. Cell Mol. Biol. Lett.; 2023; 28, 51. [DOI: https://dx.doi.org/10.1186/s11658-023-00462-9]

47. Tominari, T.; Matsumoto, C.; Tanaka, Y.; Shimizu, K.; Takatoya, M.; Sugasaki, M.; Karouji, K.; Kasuga, U.; Miyaura, C.; Miyata, S. et al. Roles of Toll-like Receptor Signaling in Inflammatory Bone Resorption. Biology; 2024; 13, 692. [DOI: https://dx.doi.org/10.3390/biology13090692]

48. Isola, G.; Polizzi, A.; Santonocito, S.; Alibrandi, A.; Williams, R.C. Periodontitis activates the NLRP3 inflammasome in serum and saliva. J. Periodontol.; 2022; 93, pp. 135-145. [DOI: https://dx.doi.org/10.1002/JPER.21-0049]

49. Yamaguchi, Y.; Kurita-Ochiai, T.; Kobayashi, R.; Suzuki, T.; Ando, T. Regulation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated periodontal disease. Inflamm. Res.; 2017; 66, pp. 59-65. [DOI: https://dx.doi.org/10.1007/s00011-016-0992-4]

50. Koca-Ünsal, R.B.; Şehirli, A.Ö.; Sayıner, S.; Aksoy, U. Relationship of NLRP3 inflammasome with periodontal, endodontic and related systemic diseases. Mol. Biol. Rep.; 2022; 49, pp. 11123-11132. [DOI: https://dx.doi.org/10.1007/s11033-022-07894-0]

51. Didilescu, A.C.; Chinthamani, S.; Scannapieco, F.A.; Sharma, A. NLRP3 inflammasome activity and periodontal disease pathogenesis–A bidirectional relationship. Oral Dis.; 2024; 30, pp. 4069-4077. [DOI: https://dx.doi.org/10.1111/odi.15005] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38817019]